It is plausible that the venous thrombotic events are related to increased thrombin generation associated with the bispecific antibody interacting with coagulation factors in aPCC. 3 One of the venous thrombotic events was associated with consumptive coagulopathy.
Emicizumab is a bispecific antibody that activates FX to FXa in the absence of FVIII.
It has been shown to reduce bleeding episodes in people with haemophilia A complicated by a FVIII inhibitor. Despite the protection against bleeds, some breakthrough bleeds are inevitable and these may require additional haemostatic treatment.
Emicizumab has been associated with severe adverse events when co-administered with activated prothrombin complex concentrate. To minimize the risk of adverse events, the UK Haemophilia Centre Doctors' Organisation issues the following updated interim guidance to its Inhibitor Guidelines for managing patients receiving Emicizumab based on the limit published information available in February 2018.
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To minimize the risk of adverse events associated with the use of Emicizumab, the UK Haemophilia Centre Doctors' Organisation issues the following interim update to its current inhibitor guidelines 4 based on the limited published data available in February 2018.
5
These guidelines are a consensus statement and have been written from the perspective of UK treaters and clinicians. Other countries may need to revise this guidance as appropriate to their healthcare system, and interim advice was issued in the USA in Nov 2017. 6 It is recognized that these guidelines may require revision as new data become available. Emicizumab has been started, a chromogenic FVIII assay using reagents containing bovine coagulation factors must be used to monitor FVIII replacement. The Bethesda assay utilizing a bovine-based FVIII chromogenic assay must be used.
| G ENER AL ADVICE

5,6
Before Emicizumab is started, samples should be taken to measure antihuman and antiporcine FVIII inhibitor titres. All treatment with Emicizumab, bypassing agents and FVIII must be recorded, including treatment given in hospital. In the United Kingdom, this should be through Haemtrack 7 and reported to the National Haemophilia Database (NHD) through routine mechanisms.
Adverse events 4,8 must be reported both to regulators through appropriate channels and, in the United Kingdom, to the NHD adverse event reporting site. Biochemical changes compatible with TMA should also be reported. Data should be collected prospectively on safety and efficacy especially in relation to coprescription to better inform future guidelines. Emicizumab has a long half-life, and the treatment recommendations described in this guidance should be observed for 6 months after stopping the drug. If a second dose of aPCC is required, the patient should be admitted to hospital for surveillance for the TMA.
| TRE ATMENT OF B LEED ING EPISODE S
Clinical haemostasis during surgery in patients receiving
Emicizumab is unpredictable and data are very limited.
Non-urgent, major surgery should be deferred until more data are available.
Due to the long half-life of Emicizumab, these treatment recommendations should be followed for 6 months after the drug has been stopped.
Once Emicizumab has been started a chromogenic assay using reagents containing bovine coagulation factors must be used to monitor FVIII replacement. The Bethesda assay utilizing a bovine reagent-based FVIII chromogenic assay must be used.
thrombosis, the initial dose of rFVIIa should not exceed 90 μg/kg. Both Emicizumab and rFVIIa cause thrombin generation and rFVIIa given at doses of 45 μg/kg 4 hourly may be efficacious for some bleeds. It is acknowledged that these dosing schedules are not based on published evidence and may need to be revised as more data become available.
The schedule is a pragmatic balance between risk of adverse events and the need to adequately treat bleeds. If lower doses or frequencies of rFVIIa do not result in an adequate haemostasis response, rFVIIa should be increased to 90 μg/kg 2 hourly before it is assumed to have failed. The total treatment period may be shortened in some cases because Emicizumab is likely to give partial protection against bleed recurrence. Clinicians and patients/parents should agree the exact dose and frequency of rFVIIa that can be used at home and when advice should be sought from the CCC if the bleed does not resolve.
If a bleed does not respond to full dose rFVIIa 9 and the antihuman FVIII inhibitor titre is low, human FVIII can be considered to treat bleeds, although it is recognized that this may lead to an amnestic response and an increased inhibitor titre. A chromogenic assay using reagents containing bovine coagulation factors should be used to ensure that adequate FVIII levels have been achieved because responses to FVIII will be unpredictable in the presence of an inhibitor. The reported episode of skin necrosis was observed in an area of skin that had been treated with local ice therapy. Whether this was causally related or co-incidental is not known; however, clinicians
should be cautious about the use of ice therapy in patients receiving concomitant Emicizumab and aPCC.
| IMMUNE TOLER AN CE INDUC TION
There are no data on the use of Emicizumab prophylaxis to prevent bleeding episodes during immune tolerance induction (ITI), and the safety of Emicizumab in this situation is unproven. Emicizumab should only be considered during ITI for patients with significant and frequent breakthrough bleeds. The dose of FVIII should be tailored to avoid high FVIII levels which will occur as FVIII tolerance is approached. 
| SU RG ERY
10
Of the 19 surgeries managed without bypassing agents, there were 5 (26%) postoperatives bleeds of which 3 followed dental extractions. One of these 5 postoperative bleeds required rFVIIa treatment, this was an arthroscopic orthopaedic procedure including synovectomy and debridement. Of the 10 cases that were treated with a bypassing agent at the time of surgery (9 rFVIIa and one aPCC, doses or frequencies not reported), there were two postoperative bleeds and both required rFVIIa treatment. 
